The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.
FDA approves ensitrelvir for COVID-19 post-exposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an anti–SARS ...
FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...
The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to ...
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein. The Food and Drug Administration (FDA) has ...
OSAKA, Japan, June 01, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter "Shionogi") announced that the U.S. Food and ...
In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Following the June update that allowed for a lower dose ...
In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results